2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Announces First Quarter 2026 Financial Results and Operational Progress
Provides Regulatory Update on Tabelecleucel
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Provides a Business Update
Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Definitive Revised Proxy Statement
Correspondence